Agree ACM1Every time they demonstrate scans instead of invasive...

Agree ACM1

Every time they demonstrate scans instead of invasive biopsies this company just gets better.

RHT: Resonance Health Develops Accurate Fatty Liver Diagnostic Test

Resonance Health Limited (RHT) is pleased to report the positive results of the clinical study to assess its
new diagnostic test for the assessment of fatty liver.
The results of the study demonstrate that the MRI-based diagnostic product developed by Resonance
Health can accurately assess the severity of fatty liver disease, replacing the need for an invasive liver
biopsy.
Nearly one in three Americans have fatty liver and non-alcoholic fatty liver disease (NAFLD) is the most
common liver disease in the US and Europe. An accurate diagnosis of early stage fatty liver disease can
provide a better outcome for patients, where the condition can be addressed before the onset of organ
damage.
The test can also be used in clinical studies associated with the development of new therapies to assist in
the management of NAFLD and non-alcoholic steatohepatitis (NASH) where repeat measurements of
liver fat content are required.
The clinical study involved 46 subjects with liver disease, including NAFLD, NASH, and Hepatitis C. Each
patient underwent a liver biopsy and the degree of liver fat was scored by two independent methods and
compared to the MRI-based result, showing a high level of sensitivity and specificity for the test.
The Company has commenced the preparation of an FDA submission to gain regulatory approval for the
product.

T1